

Weight loss – the formoline L112 advantages

formoline
L112

Lipid adsorbent to:

- support reduce excess weight
- support long-term weight control
- lower cholesterol intake from diet

Product key facts


- The No. 1* slimming tablet in Germany
- Multiple award and prize winner
- Successfully launched in more than 40 countries worldwide
- Good tolerability and low side effect profile
- Medical Device Class III certified by a designated Notified Body



*A.C. Nielsen „Top Marken Diätetika 2013, Solid Oral Dosage Forms only“

**Awards translated into English: "Schlankheitsmittel des Jahres 2017", "Schlankheitsmittel des Jahres 2015", "Schlankheitsmittel des Jahres 2013", "Schlankheitsmittel des Jahres 2012", "Schlankheitsmittel des Jahres 2011", "Schlankheitsmittel des Jahres 2010", "Schlankheitsmittel des Jahres 2009", "Schlankheitsmittel des Jahres 2008", "Schlankheitsmittel des Jahres 2007",

Reduction of lipid absorption into the blood by 66 %




The reduced uptake of calories from the dietary fats has been confirmed in an in vivo placebo-controlled study. The study was carried out on two parallel treatment groups, each consisting of six adult female Göttingen minipigs. One group served as the untreated placebo group (control) and the other group was pre-treated with 2 tablets of 500 mg formoline L112.

Cnubben N.H.P. et al. (2016): A single oral dose of a polyglucosamine influences the bioavailability of [¹⁴C]-Oleic acid in adult female Göttingen minipigs. *BMC Obesity* 3(1):1-12.

Obesity parameters after 4 months

In a double-blind, placebo-controlled study, a total of 60 slightly overweight people (BMI 26–30 kg/m²) with hyperlipidaemia received a polyglucosamine preparation or placebo in combination with appropriate physical activity. The results confirmed that taking a polyglucosamine preparation combined with additional physical activity leads to a significant decrease in body weight and has a positive impact on a pre-existing metabolic syndrome (MS).

Cornelli U. et al. (2008): Use of polyglucosamine and physical activity to reduce body weight and dyslipidemia in moderately overweight subjects. *Minerva Cardioangiologica* 56(5 Suppl 1): 71 – 78.



Manufacturer: Certmedica International GmbH
 Magnolienweg 17, 63741 Aschaffenburg, Germany
www.certmedica.de

For more information:

www.L112.com